Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Evaluate Vantage Homepage
  3. Pharmaceutical Companies
  4. Merrimack
Thumbnail
May 20, 2021

Asco 2021 – Merus intrigues in pancreatic cancer

Thumbnail
April 05, 2019

Merrimack goes back to the drawing board

Vantage logo
June 28, 2018

Therapy focus – pancreatic cancer developers press on, despite failures

Vantage logo
February 16, 2018

Interview – Ipsen needs more deals to keep growth going

Article image
Vantage logo
January 10, 2018

M&A: 2017 proves snooze-worthy on the acquisition front

Pharma and biotech takeover activity slumps to a five-year low in 2017.

Article image
Vantage logo
January 08, 2018

Asia wins 2017’s mid-cap race

A cooling of the M&A climate allows Asia-based groups to come to the fore.

Article image
Vantage logo
October 05, 2017

Back to the future for small caps, but not all benefit

Oncology-focused smaller biotechs reap rich rewards, but generics groups face hard times.

Article image
Vantage logo
July 10, 2017

Strong small cap performance drives second-quarter gains

Vantage logo
April 06, 2017

Mid-cap biopharma stocks pick up in the first quarter

Vantage logo
January 24, 2017

Asco-GI – Pancreatic cancer field awaits sparse data

Vantage logo
January 10, 2017

JP Morgan day one roundup – deals and guidance abound

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

April 20, 2022

Genetic Medicine: The Next Generation

March 18, 2022

PD(L)anner - March 2022

View more...

Editor's Picks

Vantage logo
May 05, 2022

Bristol needs to get fresh

Vantage logo
May 04, 2022

The next generation of diabetes technology

Vantage logo
April 25, 2022

Nkarta: at least as good as Fate, at a tenth of the price

Vantage logo
April 26, 2022

How Gal appointment could influence strategy at Novartis

Vantage logo
May 01, 2020

US FDA approval tracker: April

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.